The application of artificial intelligence in drug discovery could be the reset button the biopharmaceutical industry desperately needs. Latest figures from Deloitte show that to take a molecule from discovery to launch is 10-12 years, with the average cost of the R&D process at $2.2bn per drug, almost double the $1.2bn calculated in 2010. Around one third of this is accounted for in the discovery phase.
Moreover, the average forecast peak sales per late-stage asset in the drug pipeline declined to $407m in 2018, less than...





